Марказий Осиё эндокринологик журнали Ҷилди 4 № 1 (2024)
NEUROSPECIFIC PROTEINS AND MAGNETIC RESONANCE SPECTROSCOPY IN THE DIAGNOSIS OF COGNITIVE DEFICITIES IN CHILDREN WITH DIABETES MELLITUS
Алиджанова Д.А, Султанова Ш.Т
Аннотатсия
Relevance.The levels of S-100 and NSE protein in the blood of 205 children with decompensated type 1 diabetes mellitus correlate with the activation of reactive gliosis and anaerobic glycolysis in the central nervous system, respectively, which is associated with disorders in the brain. Proton magnetic resonance spectroscopy analysis revealed statistically significant changes in metabolites, including increases in choline and creatine levels, and decreases in NAA levels. The use of PMRS allows one to localize brain areas associated with cognitive decline and monitor the condition of patients with diabetes in the early stages of the disease until clinical manifestations. Aim of the study. Determining the role of biomarkers in the early diagnosis of cognitive deficits in children and adolescents with type 1 diabetes Material and methods. A survey of 205 children aged 7 to 18 years suffering from type 1 diabetes was carried out, including an objective examination with anamnesis analysis; the Montreal Cognitive Assessment Scale (MoSAtest) was used to determine cognitive impairment; the emotional sphere was assessed using the method for assessing situational (ST) and personal (PT) anxiety by Ch. D. Spielberger - Yu. L. Khanin; Blood glucose, glycosylated hemoglobin, protein S-100 and neuron-specific enolase concentrations in blood serum were determined. PMRS of the brain was performed immediately after MRI of the brain; the main spectra of N-acetylaspartate, choline, creatine and their ratios were studied. Conclusion. Studying protein S-100 and NSE in blood serum, analyzing MR spectroscopy and conducting PMRS studies make it possible to localize areas of the brain responsible for cognitive decline and dynamically monitor the condition of patients with type 1 diabetes in the early stages, even before the onset of clinical symptoms. manifestations.
сахарный диабет тип 1, когнитивный дефицит, Белок S-100, Магнитно-резонансная спектроскопия, NSE (нейронно-специфическая энолаза)diabetes mellitus type 1, cognitive deficit, protein S-100 and NSE magnetic resonance spectroscopy1 tur qandli diabet, kognitiv tanqislik, protein S-100 va NSE magnit-rezonans spektroskopiyasi.
Манбаи метамаълумот: бойгонии OAI-PMH-и маҷалла · Sindex матни пурраро нигоҳ намедорад, ба манбаъ пайванд медиҳад.